{"nctId":"NCT03822377","briefTitle":"Ticagrelor Administered as Standard Tablet or Orodispersible Formulation","startDateStruct":{"date":"2019-06-27","type":"ACTUAL"},"conditions":["ST Elevation Myocardial Infarction","NSTEMI - Non-ST Segment Elevation MI"],"count":130,"armGroups":[{"label":"Ticagrelor orodispersible tablets","type":"EXPERIMENTAL","interventionNames":["Drug: Ticagrelor orodispersible tablets"]},{"label":"Ticagrelor standard tablets","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ticagrelor standard tablets"]}],"interventions":[{"name":"Ticagrelor orodispersible tablets","otherNames":[]},{"name":"Ticagrelor standard tablets","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients presenting within 12 hours from the onset of symptoms with STEMI or very high-risk NSTEMI referred for immediate (\\< 2 hours) angiography. Very high-risk NSTEMI patients include patients with haemodynamic instability or cardiogenic shock, heart failure, life-threatening arrhythmias or resuscitated cardiac arrest, intermittent ST-segment elevation, or ongoing chest pain.\n2. Informed, written consent\n3. Male or female patients, aged ≥ 18 years old\n\nExclusion Criteria:\n\n1. Age \\< 18 years\n2. Active bleeding; bleeding diathesis; coagulopathy\n3. History of gastrointestinal or genitourinary bleeding \\<2 months\n4. Major surgery in the last 6 weeks\n5. History of intracranial bleeding or structural abnormalities\n6. Suspected aortic dissection\n7. Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux.\n8. Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers, CYP3A with narrow therapeutic window\n9. Known relevant hematological deviations: Hb \\<10 g/dl, Thromb. \\<100x10\\^9/l\n10. Use of warfarin or new oral anticoagulant derivatives within the last 7 days\n11. Known severe liver disease, severe renal failure\n12. Allergy or hypersensitivity to ticagrelor or any of the excipients.\n13. Pregnancy or lactation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Evaluation of Platelet Inhibition","description":"Platelet reactivity will be measured by VerifyNow test 1 hour after Ticagrelor loading dose (LD) administered as orodispersible tablets as compared with standard formulation in 130 patients with STEMI or very high-risk NSTEMI undergoing immediate PCI.\n\nThe VerifyNow PRU Test is designed to measure P2Y12 receptor blockade. Results of the PRU Tests are reported as P2Y12 Reaction Units (PRU). PRU measures the extent of platelet aggregation in the presence of a P2Y12 inhibitor. Lower PRU levels are associated with expected antiplatelet effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"141","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients With Insufficient Antiaggregation","description":"The percent of patients with a high residual platelet reactivity (PRU \\> 208 by VerifyNow test), thus not adequately antiaggregated, 1 hour after Ticagrelor LD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Residual Platelet Reactivity at Various Timepoints","description":"Residual platelet reactivity (PRU) at 2, 4 and 6 hours measured by VerifyNow test to assess antiplatelet effect of P2Y12 inhibitors","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Relevant Bleeding Events","description":"Actionable bleeding events across the two different regimens of Ticagrelor administration, requiring diagnostic studies, hospitalization, or treatment by a health care professional (BARC type 2 or higher)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Morphine-ticagrelor Interaction","description":"Potential morphine-ticagrelor interaction will be assessed by stratified randomization according to morphine use","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence of Adverse Events Occurring During Hospital Stay","description":"Combined ticagrelor administration-related adverse events defined as in-hospital ≥2 BARC bleedings, dyspnea, ventricular pauses, allergic reactions, or vomit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":65},"commonTop":["Combined ticagrelor administration-related adverse events defined as in-hospital ≥2 BARC bleedings,"]}}}